Frontier Biotechnologies Inc. (SHSE: 688221)
Health Care · Biotechnology · CN
CN¥20.00
-8.97% today · +8.9% 1Y
Frontier Biotechnologies Inc. (SHSE: 688221) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.11B.
Over the last twelve months the share price has gained 8.9%, trading between 13.06 and 29.98.
Tweenvest scores Frontier Biotechnologies Inc. across four factors: quality 37/100, value 42/100, growth 58/100. Its strongest factor is growth.
688221 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.11B
- Revenue (TTM)
- $56.86M
- P/E
- —
- EPS
- 0.01
- Dividend yield
- —
- Beta (5Y)
- 0.89
- 52-week high
- CN¥29.98
- 52-week low
- CN¥13.06
- Avg volume (3M)
- —
- Shares outstanding
- 374.58M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $464.58B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $238.06B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $183.64B | $148.09 | -0.01% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.72B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $81.36B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $65.40B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $59.75B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.19B | AU$172.44 | -0.69% |
Figures last refreshed Aug 18, 2026.